# Edward Hu

> Edward Hu is a Series A investor at WuXi AppTec (Shanghai) backing Biotechnology and Therapeutics. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [WuXi AppTec](https://shizune.co/investors/profile/wuxi-apptec)
- Location: Shanghai, China
- Total investments: 5
- Last investment: Feb 2021
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/edward-hu-5995113/

Edward Hu is a Series A investor at WuXi AppTec in Shanghai focused on Biotechnology and Therapeutics. Formerly Senior Vice President and Chief Operating Officer at Tanox, responsible for operations, finance, IT, project management and strategic planning. MBA and M.S. in Chemistry from Carnegie Mellon University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Therapeutics | 2 | 40% |
| Pharmaceutical | 2 | 40% |
| Medical | 1 | 20% |
| Life Science | 1 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series B | 2 | 40% |
| Series C | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 60% |
| China | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AnchorDx | Guangzhou Baseline Medical is committed to building a world-class clinical application of high-throughput sequencing and R & D platform to become the leading global provider of precision medical solutions. The company's core team has more than 20 years of senior industry experience, involved in cancer genomics, genetics and bioinformaticsand other fields.Based on its core technical advantages, the Company aims at precision medicine, establishes a cooperative relationship with middle and downstream enterprises in the industry, and forms a complete industrial chain from academic research to clinical product transformation. It has also established close cooperation with many large-scale third-party inspection agencies including Illumina, Well-known domestic and foreign hospitals and research institutes to establish cooperative relations, the development of a series of independent intellectual property rights and international competitiveness of clinical testing products for patients, doctors and medical institutions to provide accurate, convenient and comprehensive services. | $40M | Series C | Feb 22, 2021 |  |
| LifeMine Therapeutics | Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology. Founded by Gregory Verdine, PhD, Rick Klausner, MD and WeiQing Zhou, MBA, LifeMine Therapeutics is headquartered in Cambridge, Massachusetts. | $70M | Series A | Sep 18, 2017 |  |
| Vivace Therapeutics | Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway. At Vivace Therapeutics, they pursue their work with passion, driven by a conviction to help people fight cancer and live life to the fullest. Based in the San Francisco Bay Area, Vivace Therapeutics is anoncology-focused portfolio-based drug discovery and development company adopting a capital-efficient and modality-indifferent approach to bring novel therapies to patients in need. Their experienced management team and world-class scientists work to advance promising drugs and therapeutic technologies that they believe can help conquer cancer. | $25M | Series B | Jun 28, 2017 |  |
| TruTag Technologies | TruTag Technologies, Inc. is a leading authentication and technology solution provider serving businesses and governments around the world. TruTag has the most advanced precision-fabricated, cGMP nano-porous silica manufacturing operation in the world for product authentication across a broad range of industries including pharmaceuticals, food,consumer products, and industrial & electronic parts. TruTag’s authentication platform is complemented by its’ advanced hyperspectral imaging technology, which is focused on providing powerful next-generation inline quality assurance solutions and diagnostics.TruTag Technologies has been recognized by the SPIE Prism Awards, the Edison Awards, Fast Company, R&D 100, and was selected a Technology Pioneer by the World Economic Forum as one of the most influential technology companies in the world. | $21.3M | Series B | Mar 01, 2015 |  |
| TruTag Technologies | TruTag Technologies, Inc. is a leading authentication and technology solution provider serving businesses and governments around the world. TruTag has the most advanced precision-fabricated, cGMP nano-porous silica manufacturing operation in the world for product authentication across a broad range of industries including pharmaceuticals, food,consumer products, and industrial & electronic parts. TruTag’s authentication platform is complemented by its’ advanced hyperspectral imaging technology, which is focused on providing powerful next-generation inline quality assurance solutions and diagnostics.TruTag Technologies has been recognized by the SPIE Prism Awards, the Edison Awards, Fast Company, R&D 100, and was selected a Technology Pioneer by the World Economic Forum as one of the most influential technology companies in the world. | $16.8M | Series A | Jun 16, 2014 |  |

5 of 5 investments shown.

## Co-investors
- [Polar Investment Fund, LLC](https://shizune.co/investors/profile/polar-investment-fund-llc) — VC Fund, 2 deals together
- [Acer](https://shizune.co/investors/profile/acer) — VC Fund, 1 deal together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 1 deal together
- [Arocrest Capital Management](https://shizune.co/investors/profile/arocrest-capital-management) — VC Fund, 1 deal together
- [Atlantis Investment Management](https://shizune.co/investors/profile/atlantis-investment-management) — VC Fund, 1 deal together
- [Mission BioCapital](https://shizune.co/investors/profile/bioinnovation-capital) — VC Fund, 1 deal together

## About WuXi AppTec

VC Fund · Shanghai, China

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theproductivity of advancing healthcare products through cost-effective and efficient solutions,With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,900 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated".

5 contacts available at WuXi AppTec.

| Name | Title | Profile |
| --- | --- | --- |
| Edward Hu | Co-CEO | https://shizune.co/investors/profile/edward-hu |
| Ellis Chu | Chief Financial Officer | https://shizune.co/investors/profile/ellis-chu |
| Ge Li | Founder, Chairman and CEO | https://shizune.co/investors/profile/ge-li |
| Juan Lagos | Associate Director Upstream Process Development | https://shizune.co/investors/profile/juan-lagos |
| Lina Huang | Senior Director Accounting | https://shizune.co/investors/profile/lina-huang |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Edward Hu invest in?

Edward Hu invests primarily in Biotechnology, Therapeutics and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Edward Hu last invest?

The most recent investment recorded for Edward Hu closed in Feb 2021. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co